Oncotelic Therapeutics Inc. (OTCQB: OTLC) has unveiled PDAOAI, a novel evidence-interrogation platform designed to address critical challenges in biotech research by enabling researchers to surface testable hypotheses from the global TGF-β literature. The platform indexes more than 125,000 PubMed abstracts on TGF-β signaling, allowing scientists to interrogate the evidence for hypotheses rather than relying on opaque, black-box predictions.
This hypothesis-first approach directly tackles a core problem in biomedical research: reducing training-set bias and building transparent, reproducible chains from question to evidence to hypothesis. By organizing and connecting large volumes of biomedical literature, PDAOAI helps researchers identify patterns and generate hypotheses with direct links to supporting evidence, fostering a more rigorous and auditable research process.
The launch of PDAOAI comes amid a structural transition in pharmaceutical research and manufacturing. Regulatory agencies are raising expectations around data integrity and traceability, while the industry moves from retrospective audits toward continuous, AI-enabled monitoring systems. Drug discovery is also being reshaped by the growing availability of large-scale biomedical data and tools to interrogate it at scale. Both shifts reflect a common reality: manual processes and isolated datasets are no longer sufficient in an environment where scientific literature expands rapidly and regulatory demands require continuous, defensible documentation.
Recent industry coverage has placed Oncotelic alongside major companies such as Rockwell Automation, Emerson Electric, Thermo Fisher Scientific, and Danaher as contributors to the pharmaceutical sector's shift toward AI-integrated operations. This recognition underscores the relevance of PDAOAI's evidence-interrogation approach in an industry increasingly focused on transparency and reproducibility.
The PDAOAI platform differentiates itself from traditional predictive models that are trained to replicate historical datasets. Instead, it employs a retrieval-and-interrogation methodology, enabling researchers to directly link their questions to the underlying evidence. This approach aims to mitigate the biases inherent in training datasets and provide a clear, auditable trail from query to conclusion.
For Oncotelic Therapeutics, the platform represents a strategic response to the evolving needs of pharmaceutical research. By providing tools that enhance the transparency and reproducibility of hypothesis generation, PDAOAI could help researchers navigate the complexities of biomedical data while meeting regulatory expectations for data integrity. As the industry continues to embrace AI and automation, platforms like PDAOAI may play a crucial role in ensuring that these technologies are used responsibly and effectively.
For more information about Oncotelic Therapeutics and the latest news, visit the company's newsroom at ibn.fm/OTLC.
